Key result
EPO and NESP increase endothelial ADMA levels by impairing DDAH activity via oxidative stress.
Why the study?
Recombinant human erythropoietin therapy frequently causes hypertension, and the effects of epoetin beta or darbepoetin alpha on ADMA levels in endothelial cells were unclear.
Does epoetin beta or darbepoetin alpha increase asymmetric dimethylarginine (ADMA) levels in endothelial cells?
Population
Endothelial cells from the third passage
Comparison
Epoetin beta or darbepoetin alpha at various concentrations vs control
Design
Preclinical experimental study
Follow-up
24 hours
Authors
Loading...
EPO/NESP effects on endothelial ADMA in vitro; leaves open mechanistic role in EPO-associated hypertension of renal failure.
Does epoetin beta or darbepoetin alpha increase asymmetric dimethylarginine (ADMA) levels in endothelial cells?
Erythropoietin increases ADMA accumulation in endothelial cells by impairing DDAH activity via oxidative stress, providing a potential mechanism for EPO-induced hypertension.
Scalera et al. (2005) studied this question. Epoetin beta (EPO) or darbepoetin alpha (NESP) vs. Control was evaluated on ADMA concentration in the cell culture medium. Exposure of endothelial cells to EPO or NESP significantly increased ADMA concentration in a dose-dependent manner by impairing DDAH activity via increased oxidative stress.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: